Show simple item record

HPV16 antibodies as risk factors for oropharyngeal cancer and their association with tumor HPV and smoking status.

dc.contributor.author Anderson, KS
dc.contributor.author Dahlstrom, KR
dc.contributor.author Cheng, JN
dc.contributor.author Alam, R
dc.contributor.author Li, G
dc.contributor.author Wei, Q
dc.contributor.author Gross, ND
dc.contributor.author Chowell, D
dc.contributor.author Posner, M
dc.contributor.author Sturgis, EM
dc.coverage.spatial England
dc.date.accessioned 2015-10-07T16:20:40Z
dc.date.issued 2015-07
dc.identifier http://www.ncbi.nlm.nih.gov/pubmed/25957822
dc.identifier S1368-8375(15)00186-4
dc.identifier.uri https://hdl.handle.net/10161/10670
dc.description.abstract BACKGROUND: Antibodies (Abs) to the HPV16 proteome increase risk for HPV-associated OPC (HPVOPC). The goal of this study was to investigate the association of a panel of HPV16 Abs with risk for OPC as well as the association of these Abs with tumor HPV and smoking status among patients with OPC. METHODS: IgG Abs to the HPV16 antigens E1, E2, E4, E5, E6, E7, L1, L2 were quantified using a programmable ELISA assay. Sera were obtained from 258 OPC patients at diagnosis and 250 healthy controls. HPV16 tumor status was measured by PCR for 137 cases. Multivariable logistic regression was used to calculate odds ratios for the association of HPV16 Abs with risk for OPC. RESULTS: HPV16 E1, E2, E4, E5, E6, E7 and L1-specific IgG levels were elevated in OPC patients compared to healthy controls (p<0.05). After multivariable adjustment, Ab positivity for NE2, CE2, E6, and/or E7 was associated with OPC risk (OR [95% CI], 249.1 [99.3-624.9]). Among patients with OPC, Ab positivity for these antigens was associated with tumor HPV status, especially among never or light smokers (OR [95% CI], 6.5 [2.1-20.1] and OR [95% CI], 17.5 [4.0-77.2], respectively). CONCLUSIONS: Antibodies to HPV16 proteins are associated with increased risk for HPVOPC. Among patients with OPC, HPV16 Abs are associated with tumor HPV status, in particular among HPV positive patients with no or little smoking history.
dc.language eng
dc.relation.ispartof Oral Oncol
dc.relation.isversionof 10.1016/j.oraloncology.2015.04.011
dc.subject Antibodies
dc.subject Biomarker
dc.subject HPV
dc.subject Head and neck cancer
dc.subject Oropharyngeal cancer
dc.subject Serology
dc.subject Aged
dc.subject Antibodies, Viral
dc.subject Case-Control Studies
dc.subject Enzyme-Linked Immunosorbent Assay
dc.subject Female
dc.subject Human papillomavirus 16
dc.subject Humans
dc.subject Immunoglobulin G
dc.subject Logistic Models
dc.subject Male
dc.subject Middle Aged
dc.subject Oropharyngeal Neoplasms
dc.subject Risk Factors
dc.subject Smoking
dc.title HPV16 antibodies as risk factors for oropharyngeal cancer and their association with tumor HPV and smoking status.
dc.type Journal article
pubs.author-url http://www.ncbi.nlm.nih.gov/pubmed/25957822
pubs.begin-page 662
pubs.end-page 667
pubs.issue 7
pubs.organisational-group Clinical Science Departments
pubs.organisational-group Duke
pubs.organisational-group Duke Cancer Institute
pubs.organisational-group Institutes and Centers
pubs.organisational-group Medicine
pubs.organisational-group Medicine, Medical Oncology
pubs.organisational-group School of Medicine
pubs.publication-status Published
pubs.volume 51
dc.identifier.eissn 1879-0593


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record